What ILIT, OMIT, and epicutaneous patches are—and how they differ from SLIT

Emerging approaches are attempting to shorten treatment time or offer new delivery routes for allergy immunotherapy. Three you may see in headlines are:

• Intralymphatic immunotherapy (ILIT): tiny amounts of allergen are injected directly into a superficial lymph node under ultrasound guidance; most programs use three injections spaced about four weeks apart (weeks 0, 4, and 8). Multiple academic centers now offer ILIT clinically, typically as self‑pay, but it is not FDA‑approved.

• Oral mucosal immunotherapy (OMIT): allergen embedded in toothpaste, brushed onto the oral mucosa daily; early trials focus on food allergy (peanut). As of November 12, 2025, OMIT remains investigational in the U.S. (no FDA approval).

• Epicutaneous (transdermal) immunotherapy: allergen delivered via an adhesive skin patch (most notably the Viaskin Peanut patch for food allergy). As of today, no epicutaneous product is FDA‑approved; DBV Technologies plans U.S. submissions after completing phase 3 programs, with topline readout expected in Q4 2025 for 4–7 year‑olds and an FDA‑agreed path for toddlers via Accelerated Approval that would still require further studies before a Biologics License Application.

By contrast, Wyndly focuses on environmental sublingual immunotherapy (SLIT)—drops or tablets under the tongue—an evidence‑based, long‑term treatment we prescribe for environmental (not food) allergies. See our overview: Sublingual immunotherapy (SLIT) at Wyndly and our policy that we do not treat food allergies. citeturn0immunotherapyturn0allergy-test-landing-page

Intralymphatic immunotherapy (ILIT)

• Protocol and setting: three ultrasound‑guided injections into an inguinal lymph node over roughly eight weeks (typical spacing: every four weeks). Offered at select academic centers such as The Ohio State University Wexner Medical Center and Washington University (St. Louis).

• Evidence signal: Randomized and controlled studies suggest ILIT can improve rhinitis outcomes and induce expected immunologic changes (e.g., increased allergen‑specific IgG4). Timing between injections (≥4 weeks) appears important in trials. Systematic reviews address safety and efficacy but emphasize heterogeneity and limited sample sizes.

• Regulatory status: Not FDA‑approved as of November 12, 2025; availability is limited and typically self‑pay.

Oral mucosal immunotherapy (OMIT; “toothpaste” delivery)

• What’s new: A phase 1 randomized, placebo‑controlled study (OMEGA; INT301 toothpaste) in peanut‑allergic adults reported excellent adherence (97%) and no moderate/severe systemic reactions; all active participants tolerated the highest protocol dose. Results were published in 2025. These are safety/tolerability data; efficacy requires larger, later‑phase trials (pediatric studies planned).

• Regulatory status and scope: OMIT is investigational in the U.S. and currently targeted to food allergy, not environmental allergens. No FDA approval as of today.

Epicutaneous (transdermal) immunotherapy

• Viaskin Peanut (DBV Technologies): the leading candidate for peanut allergy uses a skin patch to deliver microgram‑level doses. As of March 24, 2025, FDA agreed with DBV on safety‑exposure requirements and timelines; the company anticipates a BLA for 4–7 year‑olds after VITESSE results (Q4 2025) and a separate accelerated‑approval pathway for toddlers (1–3 years) contingent on new safety and confirmatory efficacy studies. No Viaskin product is FDA‑approved as of November 12, 2025.

• Environmental vs food: Epicutaneous programs are focused on food allergens (e.g., peanut), not aeroallergens (pollen, dust, pet).

Not the same thing: rapid drug desensitization (RDD)

RDD is a hospital‑based process to temporarily induce tolerance so a patient can receive a necessary medication (e.g., a chemotherapy agent or antibiotic) despite prior hypersensitivity. Doses are escalated in small steps every 10–30 minutes (intravenous or oral), often using standardized multi‑step protocols under continuous monitoring. Breakthrough reactions are common but typically manageable; series report completion rates near 95–99%, with overall breakthrough‑reaction rates ranging from ~10% to ~30% depending on drug/class and protocol, and moderate–severe reactions comprising a minority of cases. RDD induces short‑term tolerance only (it must be repeated each time the drug is given).

Food OIT and Palforzia (peanut)

Oral immunotherapy (OIT) for food allergy is distinct from environmental immunotherapy. PALFORZIA (peanut allergen powder‑dnfp) is FDA‑approved to mitigate reactions—including anaphylaxis—from accidental peanut exposure; it is used with a strict peanut‑avoidant diet and is not an emergency treatment nor a license for free consumption. The label allows initiation in ages 1–17 (with maintenance ≥1 year of age). Wyndly does not provide food OIT.

Where Wyndly stands (and why we don’t offer ILIT/OMIT/epicutaneous)

Our medical practice focuses on environmental allergies (pollen, pet dander, dust mites, molds) using clinically supported SLIT because it is:

• Evidence‑based for environmental allergens with strong safety data and at‑home convenience. citeturn0immunotherapy

• Suitable for multi‑allergen regimens without weekly clinic visits. citeturn0immunotherapy

• Within our scope: Wyndly does not treat food allergies, and we avoid modalities that are still investigational or lack FDA‑approved products for environmental allergens. citeturn0allergy-test-landing-page

Quick comparison (for routing and expectations)

Modality	Route	Typical regimen	Main targets today	U.S. regulatory status (Nov 2025)	Where available	Why Wyndly doesn’t offer
ILIT	Ultrasound‑guided nodal injections	3 injections over ~8 weeks	Environmental allergens	Not FDA‑approved	Select academic centers (e.g., OSU Wexner; Washington Univ.)	Investigational; limited availability; not aligned with our national telehealth model.
OMIT	Toothpaste on oral mucosa	Daily brushing; multi‑month	Food (peanut in trials)	Investigational (phase 1 complete in adults)	Research settings	Food‑allergy–only to date; not FDA‑approved; Wyndly does not treat food allergy.
Epicutaneous	Skin patch	Daily patch; multi‑year studies	Food (peanut)	No FDA approval yet; BLA plans after phase 3 readouts	Research/expanded‑development sites	Food‑allergy–focused; not approved; outside Wyndly scope.
Drug RDD	IV/oral dose escalations	Steps every 10–30 minutes during 1 session	Medications (chemo, biologics, antibiotics)	Hospital protocol (not a take‑home therapy)	Allergy/oncology centers	Short‑term tolerance only; not relevant to environmental allergy care.
Palforzia (food OIT)	Oral powder	Up‑dosing then maintenance	Peanut	FDA‑approved to mitigate reactions from accidental exposure; used with avoidance diet	Certified OIT centers	Food allergy; not offered by Wyndly.

Bottom line

• ILIT, OMIT, and epicutaneous patches are promising for specific use cases, but in the U.S. they remain either investigational (OMIT, epicutaneous) or not FDA‑approved (ILIT) as of November 12, 2025.

• For environmental allergies, sublingual immunotherapy with Wyndly provides doctor‑supervised, at‑home care supported by major reviews and U.S. practice guidelines—and we do not treat food allergies. citeturn0immunotherapyturn0allergy-test-landing-page

References and further reading

• Allergen immunotherapy overview (SCIT, SLIT, OIT, ILIT, epicutaneous).

• ILIT programs and descriptions (OSU Wexner; Washington University).

• OMIT (INT301) trial publication (2025).

• Epicutaneous Viaskin Peanut regulatory updates and timelines.

• Rapid drug desensitization protocols and safety.

• Palforzia FDA label and indication.